Clinical Trial Update: Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the urate-lowering activity and safety of oral BCX4208 in gout has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• BCX4208 (BCX4208)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Gout | Phase 2 | Status: COMPLETED